growth%20hormone%20deficiency%20(pediatric)
GROWTH HORMONE DEFICIENCY (PEDIATRIC)
Growth hormone deficiency is a congenital or an acquired growth hormone axis disruption in the higher brain, hypothalamus or pituitary which results in short stature.
It may occur at any age.
Short stature is often the only feature present in patients with growth hormone deficiency and other causes of subnormal growth rate.
Etiology may be congenital conditions (eg defective pituitary development that leads to pituitary aplasia, empty sella, encephalocele, midline defects) or acquired conditions (eg tumors of the hypothalamic-pituitary region, cranial irradiation, infiltrative disease).

Monitoring

Prescribed End Points

  • IGF-I in normal range for age and sex
    • Increase dose if IGF-I is low and decrease dose if IGF-I is above normal range
  • Improvement in blood lipid profile, body composition (change in lipolysis and increase in bone density) and waist-hip ratio
  • Increased muscle strength and exercise performance
  • Reduction in cardiovascular risk factors

Patient Monitoring

  • Close follow-up care with an endocrinologist is recommended to monitor the child’s growth, assessment of potential adverse effects, and to adjust the dose of growth hormone (GH) therapy
  • Initial follow-up should be every month; thereafter, visits may be less frequent but should be at least 2x/year
  • Children on growth hormone (GH) therapy should be evaluated every 3-6 months, with increases in height and height velocity as the most important indicators of response
  • Monitor thyroid function every 6 months
  • Bone age, HbA1c levels, and adrenal function should also be assessed regularly
  • Monitor patients for hyperglycemia because growth hormone (GH) may reduce insulin sensitivity; patients with diabetes mellitus (DM) may need to adjust their insulin during treatment
    • Serum IGF-1 and IGFBP-3 levels should be obtained annually to effectively monitor treatment adherence & response
    • Dose should be reduced if serum IGF-1 levels increase above the normal range
  • Funduscopic examination is recommended at the start of therapy and periodically during the course of treatment
  • Growth hormone (GH) treatment is meant to be a replacement therapy and can only be expected to make short children grow at a normal growth rate
  • Most children treated with growth hormone (GH) replacement reach a normal adult height
    • Child’s growth usually increases most during the 1st years, with an average increase of 8-10 cm/year
    • Growth rate slows down over the next several years
  • Re-evaluation should be done once patient completed
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Aug 2018
Despite the absence of a substance use problem, regular cannabis use is associated with psychosocial impairment among adolescents and young adults, a study suggests. On the other hand, regular users with cannabis use disorder appear to exhibit high psychiatric comorbidity and more severe psychosocial impairment.
07 Sep 2018
Children with Down syndrome appear to have an elevated risk of developing severe respiratory syncytial virus (RSV) infection, a study has found.
Jairia Dela Cruz, 01 Sep 2018
Tight glycaemic control does not yield significant short-term survival gains and risk reductions for infections when compared with a conventional glucose-lowering strategy in critically ill patients in the paediatric intensive care unit, according to a meta-analysis.
01 Oct 2018
Due to varying analyses and reporting methods, fever rates in studies substantially differ. As such, there is a need for standardized fever reporting to allow comparisons between studies, according to a recent investigation.